VEGFA and polyp: [5–7] Nevertheless, previous studies report that anti-vascular endothelial growth factor (VEGF) agents, such as ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA, USA) and aflibercept (Eylea, Bayer Health Care, Berlin, Germany) have favorable effects in patients with PCV, although a large number of injections are required to maintain patients’ visual acuity with a lower polyp regression rate than that of PDT.